Role for CD4+ CD25+ Regulatory T Cells in Reactivation of Persistent Leishmaniasis and Control of Concomitant Immunity
Top Cited Papers
Open Access
- 19 July 2004
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 200 (2) , 201-210
- https://doi.org/10.1084/jem.20040298
Abstract
Reactivation of dormant infections causes an immense burden of morbidity and mortality in the world at large. Reactivation can occur as a result of immunosuppression, environmental insult, or aging; however, the cause of reactivation of such infections is often not clear. We have previously shown that persistence of the parasite Leishmania major is controlled by endogenous CD4+ CD25+ regulatory T (T reg) cells. In this report, we show that despite efficient parasite clearance at secondary sites of infection, Leishmania superinfection can cause disease reactivation at the primary site. Our results strongly suggest that T reg cells, whose numbers increase in sites of reactivation, are directly responsible for such reactivation. Depletion of CD25+ cells at the time of secondary challenge prevented disease reactivation at the site of persistent infection while strengthening the expression of immunity at the site of secondary challenge. Finally, transfer of T reg cells purified from infected mice into chronically infected mice was sufficient to trigger disease reactivation and prevent the expression of an effector memory response. Our results demonstrate that after persistence is achieved, an equilibrium between T reg cells and effector lymphocytes, which can be disturbed by superinfection, controls the efficiency of recall immune responses and disease reactivation.Keywords
This publication has 52 references indexed in Scilit:
- Activation requirements for the induction of CD4+CD25+ T cell suppressor functionEuropean Journal of Immunology, 2004
- CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell ResponsesThe Journal of Experimental Medicine, 2003
- Determinants of Response to Interleukin‐10 Receptor Blockade Immunotherapy in Experimental Visceral LeishmaniasisThe Journal of Infectious Diseases, 2003
- Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as ImmunotherapyInfection and Immunity, 2002
- Administration of plasmids expressing interleukin‐4 and interleukin‐10 causes BALB/c mice to induce a T helper 2‐type response despite the expected T helper 1‐type response with a low‐dose infection ofLeishmania majorImmunology, 2002
- Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivoNature Immunology, 2001
- The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile CureThe Journal of Experimental Medicine, 2001
- Atypical Mucocutaneous Leishmaniasis Caused by Leishmania braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-cell Responses and Remission of Lesions Associated with Antigen ImmunotherapyMemórias do Instituto Oswaldo Cruz, 1999
- The Regulation of Immunity to Leishmania MajorAnnual Review of Immunology, 1995
- Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatmentTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992